UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Isocitrate dehydrogenase mutations in myeloid malignancies

Leukemia, 2017-02, Vol.31 (2), p.272-281

2017

Volltextzugriff (PDF)

P570: REAL‐WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

HemaSphere, 2022-06, Vol.6, p.469-470

2022

Volltextzugriff (PDF)

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS

HemaSphere, 2022-06, Vol.6, p.67-68

2022

Volltextzugriff (PDF)

P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX‐BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE

HemaSphere, 2022-06, Vol.6, p.418-419

2022

Volltextzugriff (PDF)

Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials

Haematologica (Roma), 2014-08, Vol.99 (8), p.1277-1284

2014

Volltextzugriff (PDF)

Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

Drugs of Today, 2013-07, Vol.49 (7), p.447-456

2013

Volltextzugriff (PDF)

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia

Drugs of Today, 2013-04, Vol.49 (4), p.261-269

2013

Volltextzugriff (PDF)

Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6505-6505

2011

Volltextzugriff (PDF)

Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8012-8012

2010

Volltextzugriff (PDF)

An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS280-TPS280

2010

Volltextzugriff (PDF)

TNP-470 promotes initial vascular sprouting in xenograft tumors

Molecular cancer therapeutics, 2004-03, Vol.3 (3), p.335-343

2004

Volltextzugriff (PDF)

The Role of Chemistry in Fracture Pattern Development and Opportunities to Advance Interpretations of Geological Materials

Reviews of geophysics (1985), 2019-09, Vol.57 (3), p.1065-1111

2019

Volltextzugriff (PDF)

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

The lancet oncology, 2018-02, Vol.19 (2), p.216-228

2018

Volltextzugriff (PDF)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Clinical cancer research, 2022-07, Vol.28 (13), p.2753-2761

2022

Volltextzugriff (PDF)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Clinical cancer research, 2022-12, Vol.28 (24), p.5272-5279

2022

Volltextzugriff (PDF)

Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy

Journal of clinical oncology, 2022-03, Vol.40 (8), p.811-813

2022

Volltextzugriff (PDF)

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Blood cancer journal (New York), 2020-10, Vol.10 (10), p.107-107, Article 107

2020

Volltextzugriff (PDF)

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

Blood advances, 2019-10, Vol.3 (20), p.2911-2919

2019

Volltextzugriff (PDF)

Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

American journal of hematology, 2024-09, Vol.99 (9), p.1790-1801

2024

Volltextzugriff (PDF)

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

Blood advances, 2020-05, Vol.4 (9), p.1894-1905

2020

Volltextzugriff (PDF)

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Blood advances, 2022-07, Vol.6 (13), p.3879-3883

2022

Volltextzugriff (PDF)

Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

Clinical cancer research, 2022-03, Vol.28 (5), p.816-820

2022

Volltextzugriff (PDF)

Directional semivariogram analysis to identify and rank controls on the spatial variability of fracture networks

Journal of structural geology, 2018-03, Vol.108, p.34-51

2018

Volltextzugriff (PDF)

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study

American journal of hematology, 2023-09, Vol.98 (9), p.E233-E236

2023

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(87)
Berichte
(1)

Sprache

Englisch
(88)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Isocitrate dehydrogenase mutations in myeloid malignancies

P570: REAL‐WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS

P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX‐BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE

Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials

Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia

Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study

Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study

An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients

TNP-470 promotes initial vascular sprouting in xenograft tumors

The Role of Chemistry in Fracture Pattern Development and Opportunities to Advance Interpretations of Geological Materials

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

Directional semivariogram analysis to identify and rank controls on the spatial variability of fracture networks

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study

Aktive Filter

Suchergebnisse filtern